FDA status checker.

Almost never. Approval is granted for a named product, in a named formulation, for a named indication, in a named population. Semaglutide is approved for type 2 diabetes and chronic weight management, not for every metabolic outcome it gets discussed for. Tesamorelin is approved for HIV-associated lipodystrophy, which is a long way from general body composition. Reading the status column without reading the note column will mislead you.

It means the compound has no FDA approval for human use, and vendors label it for laboratory research to stay on the right side of that fact. That label is a legal position taken by the seller. It is not a purity claim, not a safety statement, not a quality grade, and not a sign that any regulator inspected the vial, its sterility, or whether the contents match the label.

It is a different thing, not automatically a better one. Investigational means the compound is in registered human clinical trials, so there is a sponsor, a protocol, a monitored safety database and a regulator watching. That structure produces real human data over time. It does not mean the compound worked, was found safe, or will ever be approved. Several compounds in this table reached late-stage trials and were then discontinued.

It is the same data published on each compound profile and each legal page on this site, arranged as one table. Status buckets come from the per-compound regulatory record, and the note names the actual approved product and indication where one exists. Nothing in this table is a new claim, and no efficacy judgement is expressed here at all.

Yes, and several will. Approvals are granted, indications are added, trial programmes are discontinued, and products are withdrawn. This table is a conservative snapshot of the public record, not a live regulatory feed. For anything that matters, check the current FDA label or the trial registry directly.

Not in this table's status column, and the distinction is worth understanding. Thymosin alpha-1 is an approved medicine in several countries, and Cerebrolysin and Cortexin are registered in others, but none of them are FDA-approved, so they sit in the investigational bucket with the foreign registration named in the note. Approval is a jurisdiction-by-jurisdiction fact.